Update on BCR/BDX

This should happen tomorrow. Here’s a press release from this morning:

BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the Ministry of Commerce of the People’s Republic of China (MOFCOM) for BD to acquire C. R. Bard (BCR), contingent on BD divesting its soft tissue core needle biopsy product line:

“MOFCOM clearance was the final regulatory approval needed to complete the Bard acquisition,” said Vincent A. Forlenza, chairman and CEO of BD. “We look forward to closing the transaction and welcoming Bard’s products and associates to the BD family.”

The proposed acquisition remains subject to the satisfaction of customary closing conditions. BD and Bard currently expect the proposed acquisition to close on Friday, Dec. 29.

Separately, BD’s proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

Posted by on December 28th, 2017 at 11:10 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.